Literature DB >> 15644784

Familial multiple endocrine neoplasia: the first 100 years.

J Aidan Carney1.   

Abstract

In 1903, Erdheim described the case of an acromegalic patient with a pituitary adenoma and three enlarged parathyroid glands. Fifty years later, Underdahl et al reported 8 patients with a syndrome of pituitary, parathyroid, and pancreatic islet adenomas. In 1954, Wermer found that the syndrome was transmitted as a dominant trait. In 1959, Hazard et al described medullary (solid) thyroid carcinoma (MTC), a tumor that later was found to be a component of two endocrine syndromes. The first of these described by Sipple in 1961 comprised pheochromocytoma, MTC, and parathyroid adenoma. The second, described by Williams et al in 1966, was the combination of mucosal neuromas, pheochromocytoma, and MTC. In 1968, Steiner et al introduced the term "multiple endocrine neoplasia" (MEN) to describe disorders featuring combinations of endocrine tumors; they designated the Wermer syndrome as MEN 1 and the Sipple syndrome as MEN 2. In 1974, Sizemore et al concluded that the MEN 2 category included two groups of patients with MTC and pheochromocytoma: one with parathyroid disease and a normal appearance (MEN 2A) and the other without parathyroid disease but with mucosal neuromas and mesodermal abnormalities (MEN 2B). Later, additional nonendocrine conditions (von Recklinghausen neurofibromatosis and von Hippel-Lindau disease) were found accompanying other more recently described familial MEN syndromes, indicating that these diseases are very complicated disorders.

Entities:  

Mesh:

Year:  2005        PMID: 15644784     DOI: 10.1097/01.pas.0000147402.95391.41

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  13 in total

1.  Medullary thyroid carcinoma: a 25-year perspective.

Authors:  Xavier Matias-Guiu; Ronald De Lellis
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

2.  Treating medullary thyroid carcinoma in a tertiary center. Current trends and review of the literature.

Authors:  E Prokopakis; M Doulaptsi; A Kaprana; S Velegrakis; Y Vlastos; G Velegrakis
Journal:  Hippokratia       Date:  2014-04       Impact factor: 0.471

Review 3.  Clinical aspects of multiple endocrine neoplasia type 1.

Authors:  Abdallah Al-Salameh; Guillaume Cadiot; Alain Calender; Pierre Goudet; Philippe Chanson
Journal:  Nat Rev Endocrinol       Date:  2021-02-09       Impact factor: 43.330

4.  Prologue to the volume: Endocrine tumors and their genetics, a perspective.

Authors:  Constantine A Stratakis
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2010-06       Impact factor: 4.690

Review 5.  Solid tumors associated with multiple endocrine neoplasias.

Authors:  Madson Q Almeida; Constantine A Stratakis
Journal:  Cancer Genet Cytogenet       Date:  2010-11

6.  Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1.

Authors:  Caroline L Lopez; Max B Albers; Carmen Bollmann; Jerena Manoharan; Jens Waldmann; Volker Fendrich; Detlef K Bartsch
Journal:  World J Surg       Date:  2016-07       Impact factor: 3.352

Review 7.  Familial non-medullary thyroid carcinoma: an update.

Authors:  Vânia Nosé
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

8.  Preoperative Imaging Overestimates the Tumor Size in Pancreatic Neuroendocrine Neoplasms Associated with Multiple Endocrine Neoplasia Type 1.

Authors:  V Polenta; E P Slater; P H Kann; M B Albers; J Manoharan; A Ramaswamy; A H Mahnken; D K Bartsch
Journal:  World J Surg       Date:  2018-05       Impact factor: 3.352

9.  Spontaneous pathology of the baboon endocrine system.

Authors:  R Guardado-Mendoza; E J Dick; L M Jimenez-Ceja; A Davalli; A O Chavez; F Folli; G B Hubbard
Journal:  J Med Primatol       Date:  2009-09-28       Impact factor: 0.667

10.  Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.

Authors:  C Romei; E Pardi; F Cetani; R Elisei
Journal:  J Oncol       Date:  2012-11-08       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.